

20 October 2009

Lifeline Scientific, Inc.
(“Lifeline” or the “Company”)

Holdings in Company

On 19 October 2009 the Company was notified that on 16 October 2009 Abingworth Bioventures V LP purchased 930,000 common shares in the Company representing 5.5% of the current issued share capital and Abingworth Bioequities Master Fund Limited purchased 570,000 common shares in the Company representing 3.4% of the current issued share capital. Both Abingworth Bioventures V LP and Abingworth Bioequities Master Fund Limited are both managed by Abingworth LLP.

Enquiries:

Lifeline Scientific, Inc.

+1 847 824 2420

David Kravitz, CEO

Seymour Pierce

+44 (0)20 7107 8000

Mark Percy / Huaizheng Peng / Sarah Jacobs

Financial Dynamics

+44 (0)20 7831 3113

Ben Brewerton